According to Zacks, “Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States. “
A number of other brokerages have also recently issued reports on KALA. ValuEngine upgraded Kala Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. Oppenheimer set a $9.00 target price on Kala Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, August 7th. Wedbush reiterated an outperform rating and set a $51.00 target price on shares of Kala Pharmaceuticals in a report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their target price on Kala Pharmaceuticals from $22.00 to $14.00 and set an overweight rating for the company in a report on Friday, November 8th. Finally, HC Wainwright reiterated a buy rating and set a $10.00 target price (down previously from $12.00) on shares of Kala Pharmaceuticals in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Kala Pharmaceuticals presently has an average rating of Buy and an average price target of $17.21.
Kala Pharmaceuticals (NASDAQ:KALA) last issued its earnings results on Thursday, November 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The firm had revenue of $1.45 million during the quarter, compared to analyst estimates of $3.56 million. As a group, equities research analysts forecast that Kala Pharmaceuticals will post -2.72 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Boston Partners lifted its position in Kala Pharmaceuticals by 542.6% during the 2nd quarter. Boston Partners now owns 118,431 shares of the company’s stock worth $756,000 after acquiring an additional 100,000 shares in the last quarter. Alambic Investment Management L.P. lifted its position in Kala Pharmaceuticals by 108.0% during the 2nd quarter. Alambic Investment Management L.P. now owns 86,487 shares of the company’s stock worth $552,000 after acquiring an additional 44,899 shares in the last quarter. Vanguard Group Inc. lifted its position in Kala Pharmaceuticals by 25.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,237,683 shares of the company’s stock worth $7,896,000 after acquiring an additional 248,287 shares in the last quarter. Northern Trust Corp lifted its position in Kala Pharmaceuticals by 4.9% during the 2nd quarter. Northern Trust Corp now owns 198,260 shares of the company’s stock worth $1,265,000 after acquiring an additional 9,183 shares in the last quarter. Finally, Wedbush Securities Inc. lifted its position in Kala Pharmaceuticals by 163.9% during the 3rd quarter. Wedbush Securities Inc. now owns 89,225 shares of the company’s stock worth $340,000 after acquiring an additional 55,410 shares in the last quarter. 67.32% of the stock is currently owned by hedge funds and other institutional investors.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
See Also: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.